All Photos
#YOURCancer is at #ASCO22 spotlighting the individuals and organizations on the frontlines of cancer care. Visit our booth to hear their stories and learn more about the work to redefine cancer care for all:
This #ASCO22, we’re sharing results from two Phase III trials in adults with chronic lymphocytic #leukemia. Learn about what these results could mean for patients with #CLL:
A reminder to mark your calendars for Chatrick Paul’s upcoming fireside chat with @endpointsnews @AKAarsalan on AstraZeneca’s highlights from #ASCO22. Register here:
There is #OnlyOneEarth and we must all play our part to protect it. As part of @TheSMI Health Systems Taskforce, we’re calling for collective action across all aspects of healthcare delivery to accelerate decarbonisation of the sector. #WorldEnvironmentDay
Retweeted by AstraZenecaUS
At ASCO 2022, we will be presenting new patient driven data that demonstrate the potential of IO to transform the way we treat #GICancers, where there continues to be a high unmet need. See more on the additional data following this year’s ASCO GI:
#SavetheDate: Chatrick Paul, SVP, Head of US Oncology, will be joining @endpointsnews @AKAarsalan for a fireside chat on AstraZeneca’s highlights from #ASCO22. Register here:
We’re committed to raising awareness of intracerebral hemorrhage (ICH) and life-threatening bleeding as we reflect upon this year’s #NationalStrokeAwarenessMonth. Read more:
We are leading a revolution in oncology, boldly challenging the status quo and pushing beyond what’s been considered possible to provide cures for cancer in every form. This ASCO 2022, see where the science has taken us:
We’re committed to advancing the science behind immune-driven diseases by unlocking the complexity of the immune system in areas of high unmet need, such as lupus nephritis:
AstraZeneca remembers and honors those who have given their lives in service to our country. #MemorialDay
Chronic lymphocytic leukemia (#CLL) can cause symptoms that may not be visible but can deeply impact the lives of patients and caregivers. During #MentalHealthAwarenessMonth and on this #WorldBloodCancerDay, learn more about the hidden impacts of this chronic disease:
In honor of #AAPIHeritageMonth, our Asian Business Resource Group hosted a discussion on “Empowerment During Racial Injustice” with @DrHanRen. Dr. Ren discussed the impacts of anti-Asian hate, racial gaslighting and how to move from Bystander to Upstander.
Tackling climate change, biodiversity loss and pollution requires bold and immediate action. In the lead up to #Stockholm50, read about the initiatives we are championing to create a resilient, sustainable and healthy future for people and the planet. #OnlyOneEarth
Retweeted by AstraZenecaUS
We announced today that the first patients have been dosed in our Phase III clinical trial in lupus nephritis (LN). Read more here:
Sharing your #lungcancer biomarker testing story can make a difference for others. Tag our partners at @LUNGevity and use #KnowYourBiomarker to share your story. #NoOneMissed
Congratulations to the @MDTechCouncil Industry Award winners. A special thanks to our very own Nathalie Fuentes, Senior Scientist, Microbiome Discovery, for presenting the #STEM Educators of the Year Award.
There are a number of subsets of #eosinophilicdiseases. Diagnosis depends on where the #eosinophils are located. Help educate your friends and family for #NEAW22. Learn more at #eosaware #NEAW
Retweeted by AstraZenecaUS
For the third year in a row, we are proud to be included on the @DiversityInc Top 50 Companies for Diversity list in the US, furthering our commitment to creating an inclusive culture and making the most of the diversity of all employees. #DITop50
Retweeted by AstraZenecaUS
Ashley Gaines, Head of US Antibody-drug Conjugate Franchise, joined a @FinancialTimes fireside chat on how to reimagine the life sciences industry business model to truly be patient-centric. Watch the full conversation here:
We are proud to support @APFEDorg in celebration of the inaugural World EOSinophilic Disease Day. Learn about eosinophil-associated diseases in our Eosinophilic Diseases Patient Charter. #EosAware
Congratulations to our very own Melinda Haren, Senior Director, Pipeline Access Strategy, for receiving a 2022 #PM360ELITE award in the #DataMiner category!…
Have you had biomarker testing for #lungcancer? We’re spreading the word with @LUNGevity on how biomarker testing can help inform treatment options. Post your biomarker story using #KnowYourBiomarker. #NoOneMissed
Tune in to watch our very own Rachele Berria, VP, US Medical, Biopharmaceuticals, during a keynote panel discussion 'Scale new trial efficiencies for all patients through common and accountable standards' at the @RE_Pharma #PharmaClinical2022. Register:
We’re sharing the latest results from our Phase III NAVIGATOR clinical trial in severe #asthma at this year’s @atscommunity International Conference. Learn more:
Tune in today to the @LupusLA spring event panel, “What’s Now & Next in Lupus?” featuring our senior medical director, Gary Bryant. We remain committed to supporting the #lupus community with meaningful resources like this event. To register:…
Transthyretin amyloidosis (#ATTR) is a systemic, progressive and fatal disease with limited treatment options. We’re proud to be presenting patient characteristics of our latest research at #PNS2022.
Today, new results from our Phase III MANDALA clinical trial in #asthma were published in @NEJM and will be presented @atscommunity’s International Conference tomorrow. #ATS2022 Learn more here:
People living with metastatic castration-resistant #prostatecancer (#mCRPC) often face a poor prognosis and limited treatment options. Join us at @AmerUrological's #AUA22 to discuss the latest in #urological diseases:
#Prostatecancer is the 2nd most common cancer in Americans assigned male at birth. Join us at @AmerUrological’s #AUA22 to learn more about our work to redefine care for men living with this disease:
We’re persistent in our mission to one day eliminate cancer as a cause of death. We’re joining @AmerUrological’s #AUA22 for the latest updates in #prostatecancer and #bladdercancer:
The majority of #breastcancer cases are diagnosed at an early stage. However, approximately 30% of people living with early breast cancer will develop incurable metastatic disease. We’re committed to discovering solutions to help reduce the risk of cancer returning.
Last week, the @US_FDA approved our therapy with our collaborators @DaiichiSankyoUS for certain patients with unresectable or metastatic #HER2-positive #BreastCancer. Learn more:
#BreastCancer is the most commonly diagnosed cancer among American women, with approximately 1 in 5 cases being #HER2-positive. Learn how we’re providing a new option to certain patients with metastatic breast cancer:
As more countries ease or lift #COVID19 restrictions, patient groups are calling on governments and health system leaders to introduce measures that address the unmet needs of the immunocompromised. Read our joint statement to learn more:
Retweeted by AstraZenecaUS
We’re proud to be supporting @POTUS’ bold #CancerMoonshot initiative to end cancer as we know it today. Read the @WhiteHouse’s announcement and more about new programs we’re partnering on to increase access to cancer screenings.
Susan Galbraith, Exec. Vice President of Oncology R&D, joined the @WhiteHouse & @theNCI for a roundtable on how to double enrolment in cancer clinical trials. “It was great to be part of this discussion and share how AstraZeneca is committed to doing our part." #CancerMoonshot…
Join us and the @atscommunity in congratulating Aaron Baugh, MD and Jamuna Krishnan, MD, MBA, BS as this year’s winners of the ATS Fellowship in Health Equity and Diversity Award.
On #WorldLupusDay, we stand with health experts and advocates to call for improved lupus care. We’re committed to advancing science-based awareness of this debilitating autoimmune disease to give those with lupus access to the care they deserve.
Join us and @LupusOrg in our fight to end the impact of lupus by wearing your purple for #WorldLupusDay.…
We’re innovating in Respiratory & Immunology to accelerate care for patients and support their communities. Read more on @statnews about our efforts from our VP, US Respiratory & Immunology, Liz Bodin:
Join us and @LupusResearch in the #ManyOneCan movement to help advance disease education and raise funds for research and advocating for better lupus treatments. #LupusAwarenessMonth…
Today, in collaboration with @DaiichiSankyoUS, we announced @US_FDA approval of our treatment for certain patients with unresectable or metastatic #HER2-positive #BreastCancer. Learn more:
Today, we announced high-level results from the DELIVER Phase III trial evaluating #cardiovascular death or worsening #heartfailure (HF) in patients with HF with mildly reduced or preserved ejection fraction. Learn more:
We’re excited to unveil this year’s judges in the Cancer Community Awards, part of our #YOURCancer program in partnership with @sciam. Learn more about the #C2Awards and our judges:
The @US_FDA has granted Priority Review for our investigational 1st -line treatment for patients with locally advanced or metastatic #BilliaryTractCancer (BTC), based on TOPAZ-1 Phase III trial. Learn more:
Ongoing gaps in asthma care, such as SABA over-reliance, have been revealed in a new Annual Asthma Patient Survey, conducted by IPSOS and funded by AstraZeneca with @Gaapp counsel on content. Here's why change is needed: #WorldAsthmaDay
Retweeted by AstraZenecaUS
We’re honored to receive top rankings on IDEA Pharma’s 2022 Pharmaceutical Innovation and Invention Index. This recognition is made possible by our incredibly passionate team and their commitment to deliver transformative science for patients.
2022 is off to a positive start at AstraZeneca with strong Q1 results announced today. We look forward to another year of progress and providing patients all over the world access to our life-saving medicines. $AZN
Retweeted by AstraZenecaUS
Camille Hertzka, VP, Head of Oncology, US Medical, was recently featured in a @PharmExec episode discussing the challenges and opportunities in treating #oncology today and sharing her personal and professional experiences in the space.
Martha Orzechowski, US Advocacy & Alliance, joined the #NMQFLeadershipSummit to discuss the US industry's role in working together for #healthequity." The time to advance health equity is NOW and success depends on sustainable collaboration at national, regional & local levels.”
Twiends™ uses the Twitter™ API, displays it's logo & trademarks, and is not endorsed or certified by them. These items remain the property of Twitter. We do not sell followers, we only provide display advertising. Bots & fake accounts are not permitted on twiends. © 2009
Grow Your Twitter Free
Want To Grow Your Twitter?
We help other people find and follow you on Twitter.
Key Info:
Started in 2009
Over 6 million signups
Country targeting provided
We never auto tweet to your timeline
We never auto follow others
We actively moderate our community
Please Share
Please upgrade your browser  chrome